https://www.selleckchem.com/pr....oducts/p5091-p005091
1 for superiority). The median progression-free survival was 16 versus 12 months (HR = 0.73; = 0.01 for noninferiority, .01 for superiority). Toxicities were similar, except that more patients in the PC arm had hematologic toxicity and more patients in the PI arm had confusion and genitourinary hemorrhage. Among 90 eligible patients with OCS, those in the PC arm had longer OS (30 25 months) and progression-free survival (15 10 months) than those in the PI arm, but with limited precision, these differences were not statis
Like
Comment
Share
